Focused On-demand Library for Cilia- and flagella-associated protein 74

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9C0B2

UPID:

CFA74_HUMAN

Alternative names:

Alternative UPACC:

Q9C0B2; A4VCI2; H7C4E1; Q5T2D9; Q5T2E0; Q69YW0; Q6ZSJ4

Background:

Cilia- and flagella-associated protein 74 plays a crucial role in the movement of cilia and flagella, essential for cell motility and fluid flow across cell surfaces. This protein is integral to the central apparatus of the cilium axoneme, contributing to the precise architecture and function of sperm, as well as respiratory cilia.

Therapeutic significance:

Given its pivotal role in primary ciliary dyskinesia, particularly Ciliary dyskinesia, primary, 49, without situs inversus, understanding the function and mechanisms of Cilia- and flagella-associated protein 74 could pave the way for innovative treatments. Targeting the protein's function may offer new therapeutic avenues for managing respiratory infections and infertility associated with this condition.